PanGen Biotech Inc Asset Resilience Ratio
PanGen Biotech Inc asset resilience ratio. PanGen Biotech Inc (222110) has an Asset Resilience Ratio of 30.66% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See 222110 defensive interval ratio to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of PanGen Biotech Inc (2014–2024)
Asset resilience ratio of PanGen Biotech Inc from 2014 to 2024. This chart shows how PanGen Biotech Inc's Asset Resilience Ratio has changed over time. Read debt load of PanGen Biotech Inc for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down PanGen Biotech Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see 222110 total asset value.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | ₩0.00 | 0% |
| Short-term Investments | ₩10.05 Billion | 30.66% |
| Total Liquid Assets | ₩10.05 Billion | 30.66% |
Asset Resilience Insights
- Very High Liquidity: PanGen Biotech Inc maintains exceptional liquid asset reserves at 30.66% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
PanGen Biotech Inc Industry Peers by Asset Resilience Ratio
Compare PanGen Biotech Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Madrigal Pharmaceuticals Inc
NASDAQ:MDGL |
Biotechnology | 62.31% |
|
Verona Pharma plc
F:I9SA |
Biotechnology | 0.00% |
|
Centessa Pharmaceuticals PLC ADR
NASDAQ:CNTA |
Biotechnology | 33.37% |
|
Shanghai RAAS Blood Products Co Ltd Class A
SHE:002252 |
Biotechnology | 2.03% |
|
Beijing Tiantan Biological Products Corp Ltd
SHG:600161 |
Biotechnology | 8.08% |
|
Bavarian Nordic
CO:BAVA |
Biotechnology | 10.83% |
|
Hebei Changshan Biochem Pharma
SHE:300255 |
Biotechnology | -0.03% |
|
Tibet Cheezheng Tibetan Medicine Co Ltd
SHE:002287 |
Biotechnology | 37.31% |
PanGen Biotech Inc Asset Resilience Ratio by Year (2014–2024)
PanGen Biotech Inc asset resilience ratio by year from 2014 to 2024. The table below shows the annual Asset Resilience Ratio data for PanGen Biotech Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 37.42% | ₩11.43 Billion ≈ $7.75 Million |
₩30.54 Billion ≈ $20.70 Million |
+37.20pp |
| 2023-12-31 | 0.22% | ₩45.06 Million ≈ $30.54K |
₩20.74 Billion ≈ $14.06 Million |
+0.21pp |
| 2022-12-31 | 0.01% | ₩2.00 Million ≈ $1.36K |
₩20.67 Billion ≈ $14.01 Million |
-55.22pp |
| 2021-12-31 | 55.23% | ₩23.90 Billion ≈ $16.20 Million |
₩43.28 Billion ≈ $29.33 Million |
+3.89pp |
| 2020-12-31 | 51.33% | ₩18.64 Billion ≈ $12.63 Million |
₩36.31 Billion ≈ $24.61 Million |
-11.00pp |
| 2019-12-31 | 62.34% | ₩24.36 Billion ≈ $16.51 Million |
₩39.08 Billion ≈ $26.49 Million |
-1.09pp |
| 2018-12-31 | 63.42% | ₩28.93 Billion ≈ $19.60 Million |
₩45.61 Billion ≈ $30.91 Million |
+13.46pp |
| 2017-12-31 | 49.96% | ₩17.78 Billion ≈ $12.05 Million |
₩35.59 Billion ≈ $24.12 Million |
+0.31pp |
| 2016-12-31 | 49.65% | ₩18.57 Billion ≈ $12.58 Million |
₩37.40 Billion ≈ $25.34 Million |
+43.72pp |
| 2014-12-31 | 5.93% | ₩1.00 Billion ≈ $677.69K |
₩16.87 Billion ≈ $11.43 Million |
-- |
About PanGen Biotech Inc
PanGen Biotech Inc. operates as a biologics company in South Korea. It develops biosimilar products, such as EPO, recombinant factor VIII, G-CSF, etc. The company also provides CHO cell lines for proteins and monoclonal antibodies; and one-stop services ranging from producer cell line development to GMP production. In addition, it offers reagents, quantitation kits, and cell based assay systems, … Read more